North Chicago, Illinois-based Abbott Laboratories (ABT) discovers, develops, manufactures, and sells healthcare products.

The last few weekends have been roiled by headlines. Here's why we took a different direction on this medical stock this week ...

For full-year 2025, the company forecast organic sales growth between 7.5% and 8.5% as well as adjusted earnings per share in the range of $5.05 and $5.25. Analysts polled by FactSet expect $42 ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

On Wednesday, Abbott Laboratories (NYSE ... Organic growth, excluding COVID-19 testing-related sales was 10.1%. Adjusted diluted earnings per share were $1.34, in line with the analyst estimates ...

Abbott Laboratories (ABT) reports robust sales growth and improved margins, setting the stage for continued success in 2025 despite market challenges.

For 2025, Abbott forecast organic sales growth of between 7.5% and 8.5%, as well as adjusted earnings per share of $5.05 to $5.25. Analysts expect $5.16 a share on $42 billion in sales.

A high throughput, highly automated test system for blood screening ... and documenting for every run. ABBOTT PRISM is designed to increase lab efficiency. It reduces manual steps and checks ...

The outlook and technical action suggest Abbott Laboratories (NYSE ... in below consensus partly because of weakness in COVID-19 testing, but organic growth is double-digit, and all segments ...

Worldwide COVID-19 testing sales were $176 million in the ... 7.5%- 8.5% and an adjusted operating margin of 23.5%- 24.0%. Abbott Laboratories expects first quarter 2025 adjusted EPS of $1.05 ...

Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying base business ...